Skip to content
Reference · Anecdotal

Reported effects in humans

What people who have used SR-17018 say it does. None of this is from clinical trials. All of it is unverified self-report. We include it because the data exists and people deserve to see it — but it should be read with the limits in mind.

Last reviewed: 2026-05-05Editorial methodology

What kind of data this is

Effects most consistently reported

  • Suppression of acute opioid withdrawal symptoms when substituted for the dependence-producing opioid
  • Minimal to absent euphoria
  • Onset approximately 30 minutes after oral dosing
  • Peak effect at approximately 2 hours
  • Duration of effect approximately 6–12 hours, with most reports clustering around 8 hours
  • Sedation at higher oral doses (~100 mg)
  • Gastrointestinal effects (constipation, occasional diarrhea or stomach gurgling)

Effects reported less consistently

  • Reduction of cravings during continued use
  • Reduction of opioid tolerance during and after a course of use
  • Mild headaches, mental fogginess, or "heavy head" sensation
  • Dissociation or depersonalization in some users
  • Sleep disturbance, vivid dreams
  • Mood lability and post-acute withdrawal-like symptoms after discontinuation

Reported community use patterns

Self-reported tapers describe a calibration period (typically 2–3 days, low frequent doses), a maintenance period (typically 4–7 days at a stable dose), and a taper period (typically 7–14 days of progressive dose reduction). Reported maintenance doses range widely — from approximately 25 mg every 8 hours (lower-tolerance users) to 100–250 mg multiple times daily (users with high-potency synthetic opioid dependence). Higher-frequency, smaller doses are commonly described as more effective for symptom control than larger, less-frequent doses.

Why this data has limits

  • Sample size: a few hundred posts at most, with substantial overlap among posters
  • No verification of substance identity (analytical confirmation is rare in this population)
  • No medical follow-up
  • Strong publication bias toward positive outcomes; people experiencing serious harm or fatal outcomes cannot post follow-ups
  • Self-reported data is subject to placebo effects, expectancy effects, and recall error

This is exactly why we are launching a third-party testing service — so that at minimum, we can answer the substance-identity part of the problem with chromatography rather than trust.

Sources cited on this page

  1. [1]r/Opioid_RCs and r/researchchemicals — community self-reports · RedditAnecdotal only; subject to severe selection and survivorship bias